Yves Rolland1, Charlotte Dupuy2, Gabor Abellan Van Kan2, Matteo Cesari2, Bruno Vellas2, Marie Faruch3, Cedric Dray4, Philipe de Souto Barreto2. 1. Gérontopôle, Department of Internal Medicine and Geriatrics, Toulouse University Hospital, Toulouse, France; INSERM U1027, University of Toulouse III, Toulouse, France. Electronic address: rolland.y@chu-toulouse.fr. 2. Gérontopôle, Department of Internal Medicine and Geriatrics, Toulouse University Hospital, Toulouse, France; INSERM U1027, University of Toulouse III, Toulouse, France. 3. Central Medical Imaging Department, Purpan University Hospital, Place du Dr Baylac, Toulouse, France. 4. INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France.
Abstract
OBJECTIVES: Screening for sarcopenia in daily practice can be challenging. Our objective was to explore whether the SARC-F questionnaire is a valid screening tool for sarcopenia (defined by the Foundation for the National Institutes of Health [FNIH] criteria). Moreover, we evaluated the physical performance of older women according to the SARC-F questionnaire. DESIGN: Cross-sectional study. PARTICIPANTS: Data from the Toulouse and Lyon EPIDémiologie de l'OStéoporose study (EPIDOS) on 3025 women living in the community (mean age: 80.5 ± 3.9 years), without a previous history of hip fracture, were assessed. MEASUREMENTS: The SARC-F self-report questionnaire score ranges from 0 to 10: a score ≥4 defines sarcopenia. The FNIH criteria uses handgrip strength (GS) and appendicular lean mass (ALM; assessed by DXA) divided by body mass index (BMI) to define sarcopenia. Outcome measures were the following performance-based tests: knee-extension strength, 6-m gait speed, and a repeated chair-stand test. The associations of sarcopenia with performance-based tests was examined using bootstrap multiple linear-regression models; adjusted R2 determined the percentage variation for each outcome explained by the model. RESULTS: Prevalence of sarcopenia was 16.7% (n = 504) according to the SARC-F questionnaire and 1.8% (n = 49) using the FNIH criteria. Sensibility and specificity of the SARC-F to diagnose sarcopenia (defined by FNIH criteria) were 34% and 85%, respectively. Sarcopenic women defined by SARC-F had significantly lower physical performance than nonsarcopenic women. The SARC-F improved the ability to predict poor physical performance. CONCLUSION: The validity of the SARC-F questionnaire to screen for sarcopenia, when compared with the FNIH criteria, was limited. However, sarcopenia defined by the SARC-F questionnaire substantially improved the predictive value of clinical characteristics of patients to predict poor physical performance.
OBJECTIVES: Screening for sarcopenia in daily practice can be challenging. Our objective was to explore whether the SARC-F questionnaire is a valid screening tool for sarcopenia (defined by the Foundation for the National Institutes of Health [FNIH] criteria). Moreover, we evaluated the physical performance of older women according to the SARC-F questionnaire. DESIGN: Cross-sectional study. PARTICIPANTS: Data from the Toulouse and Lyon EPIDémiologie de l'OStéoporose study (EPIDOS) on 3025 women living in the community (mean age: 80.5 ± 3.9 years), without a previous history of hip fracture, were assessed. MEASUREMENTS: The SARC-F self-report questionnaire score ranges from 0 to 10: a score ≥4 defines sarcopenia. The FNIH criteria uses handgrip strength (GS) and appendicular lean mass (ALM; assessed by DXA) divided by body mass index (BMI) to define sarcopenia. Outcome measures were the following performance-based tests: knee-extension strength, 6-m gait speed, and a repeated chair-stand test. The associations of sarcopenia with performance-based tests was examined using bootstrap multiple linear-regression models; adjusted R2 determined the percentage variation for each outcome explained by the model. RESULTS: Prevalence of sarcopenia was 16.7% (n = 504) according to the SARC-F questionnaire and 1.8% (n = 49) using the FNIH criteria. Sensibility and specificity of the SARC-F to diagnose sarcopenia (defined by FNIH criteria) were 34% and 85%, respectively. Sarcopenic women defined by SARC-F had significantly lower physical performance than nonsarcopenic women. The SARC-F improved the ability to predict poor physical performance. CONCLUSION: The validity of the SARC-F questionnaire to screen for sarcopenia, when compared with the FNIH criteria, was limited. However, sarcopenia defined by the SARC-F questionnaire substantially improved the predictive value of clinical characteristics of patients to predict poor physical performance.
Authors: E Dent; J E Morley; A J Cruz-Jentoft; H Arai; S B Kritchevsky; J Guralnik; J M Bauer; M Pahor; B C Clark; M Cesari; J Ruiz; C C Sieber; M Aubertin-Leheudre; D L Waters; R Visvanathan; F Landi; D T Villareal; R Fielding; C W Won; O Theou; F C Martin; B Dong; J Woo; L Flicker; L Ferrucci; R A Merchant; L Cao; T Cederholm; S M L Ribeiro; L Rodríguez-Mañas; S D Anker; J Lundy; L M Gutiérrez Robledo; I Bautmans; I Aprahamian; J M G A Schols; M Izquierdo; B Vellas Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075
Authors: Mary P Kotlarczyk; Subashan Perera; David A Nace; Neil M Resnick; Susan L Greenspan Journal: J Am Geriatr Soc Date: 2017-11-20 Impact factor: 5.562
Authors: F de Souza Orlandi; R Brochine Lanzotti; J Gomes Duarte; H Novais Mansur; M S Zazzetta; S C Iost Pavarini; M R Cominetti; S Matumoto Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075